Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 241

Results For "UST"

4033 News Found

Novartis to spin-off Sandoz business to a standalone company
News | August 28, 2022

Novartis to spin-off Sandoz business to a standalone company

Sandoz is planned to be incorporated in Switzerland and to be listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) program in the US


Philips spotlights integrated, data-driven cardiology solutions at ESC 2022
Digitisation | August 28, 2022

Philips spotlights integrated, data-driven cardiology solutions at ESC 2022

Philips AI-powered interventional and diagnostic smart systems enhances diagnostic confidence, drive greater efficiency, and improve patient outcomes


Cipla receives 6 observations from USFDA for Goa facility
Drug Approval | August 28, 2022

Cipla receives 6 observations from USFDA for Goa facility

There are no data integrity (DI) observations.


Syngene International forms a new subsidiary
News | August 28, 2022

Syngene International forms a new subsidiary

The company shall be engaged in the business of manufacturing of pharmaceutical, bio-pharmaceutical and biological products of any kind


Syngene International to acquire stake in O2 Renewable Energy II
News | August 28, 2022

Syngene International to acquire stake in O2 Renewable Energy II

A special purpose vehicle (SPV) formed by O2 Energy SG Pte Ltd, for generation and supply of renewable power


Benvic acquires specialty U.S. compounder Chemres
News | August 27, 2022

Benvic acquires specialty U.S. compounder Chemres

The ninth acquisition since 2018


US FDA inspection at Gland Pharma's Dundigal facility, Hyderabad
News | August 26, 2022

US FDA inspection at Gland Pharma's Dundigal facility, Hyderabad

The company has received 1 (ONE) observation on Form 483 with respect to ANDA filed for the product to be manufactured at the said Facility.


10th Merck Bioforum India 2022 on Sept. 6-8
News | August 26, 2022

10th Merck Bioforum India 2022 on Sept. 6-8

This Bioforum will provide the latest insights on delivering increased speed, greater flexibility and enhanced quality while reducing the cost, and risks of navigating the evolving biopharma landscape


Olaparib approved in Japan as adjuvant treatment for patients with high recurrent risk breast cancer
Drug Approval | August 26, 2022

Olaparib approved in Japan as adjuvant treatment for patients with high recurrent risk breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients


Mojocare secures US$20.6 million in Series A Funding
Healthcare | August 24, 2022

Mojocare secures US$20.6 million in Series A Funding

The funding round also saw participation from some of India's top angel investors and leading industry giants